Home/Filings/4/0001765581-25-000042
4//SEC Filing

Mulligan Seamus 4

Accession 0001765581-25-000042

CIK 0001232524other

Filed

May 12, 8:00 PM ET

Accepted

May 13, 6:51 PM ET

Size

11.6 KB

Accession

0001765581-25-000042

Insider Transaction Report

Form 4
Period: 2025-05-09
Transactions
  • Purchase

    Ordinary Shares

    2025-05-09$98.10/sh+80,684$7,915,47280,684 total(indirect: By Nerano Pharma Lim)
  • Purchase

    Ordinary Shares

    2025-05-09$99.71/sh+100$9,971100,000 total(indirect: By Nerano Pharma Lim)
  • Purchase

    Ordinary Shares

    2025-05-12$103.00/sh+1,621$166,962101,621 total(indirect: By Nerano Pharma Lim)
  • Purchase

    Ordinary Shares

    2025-05-09$98.91/sh+19,216$1,900,67899,900 total(indirect: By Nerano Pharma Lim)
Holdings
  • Ordinary Shares

    1,176,106
Footnotes (4)
  • [F1]Reflects the purchase of ordinary shares executed in multiple transactions at prices ranging from $97.56 to $98.5542. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected.
  • [F2]Shares beneficially owned by Nerano Pharma Limited, an entity owned and controlled by the reporting person and his immediate family.
  • [F3]Reflects the purchase of ordinary shares executed in multiple transactions at prices ranging from $98.56 to $99.47. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected.
  • [F4]Reflects the purchase of ordinary shares executed in multiple transactions at prices ranging from $102.97 to $103.00. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected.

Issuer

Jazz Pharmaceuticals plc

CIK 0001232524

Entity typeother

Related Parties

1
  • filerCIK 0001536639

Filing Metadata

Form type
4
Filed
May 12, 8:00 PM ET
Accepted
May 13, 6:51 PM ET
Size
11.6 KB